Nyxoah S.A. (NASDAQ:NYXH) Given Average Recommendation of “Moderate Buy” by Analysts

Nyxoah S.A. (NASDAQ:NYXH) has been given a consensus recommendation of “Moderate Buy” by the six analysts that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $20.60.

Several brokerages have recently issued reports on NYXH. Cantor Fitzgerald lifted their price target on Nyxoah from $10.00 to $14.00 and gave the company an “overweight” rating in a research note on Friday, February 9th. Piper Sandler lifted their target price on Nyxoah from $15.00 to $20.00 and gave the company an “overweight” rating in a research report on Wednesday, March 6th. Oppenheimer increased their target price on shares of Nyxoah from $17.00 to $20.00 and gave the stock an “outperform” rating in a report on Thursday, March 14th. Stifel Nicolaus lifted their price target on shares of Nyxoah from $20.00 to $27.00 and gave the company a “buy” rating in a report on Wednesday, March 20th. Finally, HC Wainwright reissued a “buy” rating and issued a $22.00 price objective (up previously from $18.00) on shares of Nyxoah in a research note on Wednesday, March 20th.

Nyxoah Trading Up 8.9 %

NYXH stock opened at $10.40 on Friday. Nyxoah has a 52 week low of $4.00 and a 52 week high of $20.00. The business has a 50-day simple moving average of $13.65 and a 200 day simple moving average of $8.60. The company has a quick ratio of 4.50, a current ratio of 4.73 and a debt-to-equity ratio of 0.12.

Nyxoah (NASDAQ:NYXH) last issued its quarterly earnings results on Tuesday, March 5th. The company reported ($0.41) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.41). The company had revenue of $1.96 million during the quarter, compared to the consensus estimate of $2.01 million. Nyxoah had a negative net margin of 993.28% and a negative return on equity of 38.58%. Equities research analysts predict that Nyxoah will post -1.78 EPS for the current fiscal year.

Institutional Trading of Nyxoah

Several hedge funds and other institutional investors have recently made changes to their positions in NYXH. ExodusPoint Capital Management LP boosted its position in Nyxoah by 44.6% during the 2nd quarter. ExodusPoint Capital Management LP now owns 18,758 shares of the company’s stock worth $150,000 after buying an additional 5,787 shares during the period. JPMorgan Chase & Co. acquired a new position in shares of Nyxoah during the first quarter worth $965,000. AXA S.A. lifted its holdings in shares of Nyxoah by 1.4% during the first quarter. AXA S.A. now owns 217,000 shares of the company’s stock worth $1,621,000 after purchasing an additional 3,000 shares during the period. Millennium Management LLC bought a new stake in shares of Nyxoah in the fourth quarter worth $51,000. Finally, Sei Investments Co. acquired a new stake in Nyxoah in the second quarter valued at $265,000.

Nyxoah Company Profile

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.